Slides
Page 1
June 2025 We are the Optejet® Company An FDA-registered Class I Medical Device
Page 2
Forward-looking Statements Except for historical information, all the statements, expectations, and assumptions contained in this presentation are forward -looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expecta tions, strategies, predictions, or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our products, product candidates, and platform technology. These statements are based on current expectations, estimates, and projections regarding our business, which are in part based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or fore casted in the forward-looking statements due to numerous factors discussed from time to time in documents that we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our and ou r licensees’ clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing and our licensees’ ability to submit applications for, obtaining and maintaining regulatory approvals for platform tec hnology and potential revenues from licensing transactions; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities, intellectual property risks, changes in legal, regulatory, legis lative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulat ory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward -looking statements. 2
Page 3
3 Today’s Eyedropper Bottle Over the past 125 years, changes in eyedropper design have done little to improve the usability of topical ophthalmic medications 1800’s Glass Pipette 1900’s Glass Pipette with Bulb and Separate Vial Today Integrated Bottle with Dropper Tip 1. Survey conducted in January 2023 with 100 people (19 - 65+ Age Range, Mean Age = 51YO) who regularly take eye drop medications respondents were asked to ranked common drug forms from easiest to administer, to most difficult to administer on a 0-10 scale (0 meaning no difficulty, 10 meaning extremely difficult). Of the 11 medication types the respondents were asked to ranked, Eye drops ranked third most difficult behind suppositories and eye ointments. The Topical Ointments were ranked the easiest to administer with an average score of 1.11, and suppositories ranked the most difficult with a score of 6.38. Comparatively, Eye Drops received an average score of 4.63 In a recent survey conducted by J. Reckner and Associates, consumers reported that taking eye drops was among the most difficult ways to self -administer medication1 Designed for Manufacturing Ease, Not Patient Ease
Page 4
Optejet® Patented Technology Delivers Gentle Mist of Medication Directly Where Needed Note: 1 Wirta DL, Walters TR, Flynn WJ, Rathi S, Ianchulev T. Mydriasis with micro-array print touch-free tropicamide-phenylephrinefixed combination MIST: pooled randomized Phase III trials. Ther Deliv. 2021 Mar;12(3):201-214; 2 Optecare is Eyenovia’s suite of digital complianceand adherence capabilities. Designed to address issues with ease-of-use and dosing precision Delivers efficacy while improving tolerability and side effects¹ Digital Optecare capabilities 2 Spray nozzle with 109 laser-drilled ports Shutter Activation button Ergonomic design Proprietary drug cartridge design with digital interface Base Unit with rechargeable battery 4
Page 5
5 Ergonomic Design to Improve Usability Eye Dropper Bottle administration requires head-tilting, squeezing, and reliance on gravity Eye Dropper Bottle tips can touch the eye surface Optejet has a recessed nozzle, protected by a shutter when not in use to prevent cross- contamination Optejet administration can be done horizontally with the push of a button
Page 6
6 Spray nozzle with 109 laser-drilled ports Mist button Proprietary, pre-filled and replaceable drug cartridge containing tropicamide and phenylephrine Fill button Base Unit with rechargeable battery CartridgeBase The unique validation studies for the device and its electronics as well as the clinical proof of its fixed combination drug product were successfully combined for the first time in front of the ophthalmic division of the FDA Optejet® is an FDA-registered Class 1 Medical Device
Page 7
Optejet® UFD cartridge can be filled by users with medication from a typical eye drop bottle Patients can fill sterile Optejet cartridges with medications from typical eye drop bottles • Any low-viscosity liquids, preserved solutions, or suspensions will be compatible • The same base can be used with multiple cartridges filled with different prescriptions • Single-use cartridges are not refillable and can be programmed to shut off electronically after a set number of days or number of sprays Sealed port with filled cartridge ready for use Door closes to seal port Empty cartridge supplied with funnel for User-filled medication 3 2 1 7
Page 8
The Future: Business Opportunities in Digital Eye Health Optejet® Enables Compliance Tracking for Topical Ophthalmic MedicationsThe Optejet® is capable of automatically tracking usage • Treatment adherence and compliance is typically a primary determinant of therapy success • The Optejet® can record each dose administered and can send information to a companion app • Patients could receive reminders to take doses and track their compliance progress • HCPs would have real -time information to make quick and informed decisions • Potential Payers could benefit from population -based efficacy analyses and better outcomes where patient compliance is an issue 8
Page 9
9 Treatment Compliance via Optecare Technology Only Optejet comes with built-in Optecare technology to track and communicate patient compliance data In clinical studies, the daily treatment compliance of the first 28 subjects was well above what was predicted Treatment adherence and compliance are typically a primary determinant of therapy success Payers are strongly motivated to include therapies on formulary that improve outcomes1 9 1 Data on file with E yenovia. 2 Naito 2018: Naito T, Yoshikawa K, Namigu ch i K, Mizoue S, Sh iraishi A, et al. (2018) Comparison of success rates in eye drop instillation b etween sitting position and supine position . PLOS ONE 13(9): e0204363. Patel 1995: Patel S C, Spaeth GL. Compliance in patients p rescrib ed eyedrops for glaucoma. Oph thalmic Su rg. 1995 May -Jun;26(3):233 -6. Winfield, 1990: Win field AJ, Jessiman D, Williams A, Esakowitz L. A study o f the causes of non -compliance by patients prescr ibed eyedro ps. Br J Ophthalmol . 1990 Aug;74(8):477 -80. 3. Matsui, 1997: Matsui DM. Drug comp liance in ped iatrics. Clinical and resear ch issues. Ped iatr Clin North Am. 1997 Feb;44(1):1 -14.
Page 10
10 Broad Intellectual Property Portfolio Through 2041 • Key claims covered with multiple patents – 18 US Patents Issued; 8 pending – 89 foreign issued; 33 pending • Optejet products are considered “ophthalmic metered sprays” by the FDA and cannot be substituted with eye drops • Regulatory approval pathway through the FDA drug division adds another layer of protection
Page 11
11 Near Term Timeline July 2025 August September October 1H 2026 VALIDATION STUDIES Optejet UFD Registration Optejet UFD Commercial Availability
Page 12
12 Existing Licensees Artic Vision, China Sublicense from Senju for portions of the Optejet® Family in Greater China and Korea Senju Pharmaceuticals, Japan License for the Optejet ® Product Family for all of Asia